Reducing irf4, dusp22, or flj43663 polypeptide expression

Abstract

This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided.

1 . A method for reducing IRF4 polypeptide expression within a T-cell lymphoma cell, said method comprising:
 a) identifying a mammal having a T-cell lymphoma cell, and   b) administering an IRF4 polypeptide inhibitor to said mammal under conditions wherein said IRF4 polypeptide expression is reduced.   
     
     
         2 . The method of  claim 1 , wherein said mammal is a human. 
     
     
         3 . The method of  claim 1 , wherein said T-cell lymphoma cell is a peripheral T-cell lymphoma cell. 
     
     
         4 . The method of  claim 3 , wherein said peripheral T-cell lymphoma cell is a primary cutaneous type anaplastic large cell lymphoma cell. 
     
     
         5 . The method of  claim 1 , wherein said administering step comprises intravenous administration. 
     
     
         6 . The method of  claim 1 , wherein said IRF4 polypeptide inhibitor is an siRNA molecule capable of inducing RNA interference against mRNA encoding an IRF4 polypeptide. 
     
     
         7 . A method for reducing DUSP22 polypeptide expression within a T-cell lymphoma cell, said method comprising:
 a) identifying a mammal having a T-cell lymphoma cell, and   b) administering an DUSP22 polypeptide inhibitor to said mammal under conditions wherein said DUSP22 polypeptide expression is reduced.   
     
     
         8 . The method of  claim 7 , wherein said mammal is a human. 
     
     
         9 . The method of  claim 7 , wherein said T-cell lymphoma cell is a peripheral T-cell lymphoma cell. 
     
     
         10 . The method of  claim 9 , wherein said peripheral T-cell lymphoma cell is a primary cutaneous type anaplastic large cell lymphoma cell. 
     
     
         11 . The method of  claim 7 , wherein said administering step comprises intravenous administration. 
     
     
         12 . The method of  claim 7 , wherein said DUSP22 polypeptide inhibitor is an siRNA molecule capable of inducing RNA interference against mRNA encoding an DUSP22 polypeptide. 
     
     
         13 . A method for reducing FLJ43663 polypeptide expression within a T-cell lymphoma cell, said method comprising:
 a) identifying a mammal having a T-cell lymphoma cell, and   b) administering an FLJ43663 polypeptide inhibitor to said mammal under conditions wherein said FLJ43663 polypeptide expression is reduced.   
     
     
         14 . The method of  claim 13 , wherein said mammal is a human. 
     
     
         15 . The method of  claim 13 , wherein said T-cell lymphoma cell is a peripheral T-cell lymphoma cell. 
     
     
         16 . The method of  claim 15 , wherein said peripheral T-cell lymphoma cell is a primary cutaneous type anaplastic large cell lymphoma cell. 
     
     
         17 . The method of  claim 13 , wherein said administering step comprises intravenous administration. 
     
     
         18 . The method of  claim 13 , wherein said FLJ43663 polypeptide inhibitor is an siRNA molecule capable of inducing RNA interference against mRNA encoding an FLJ43663 polypeptide. 
     
     
         19 . A method for assessing a lymphoma of a mammal, wherein said method comprises:
 (a) detecting an IRF4 translocation within said lymphoma, and   (b) classifying said mammal as having cutaneous anaplastic large-cell lymphoma.   
     
     
         20 . The method of  claim 19 , wherein said mammal is a human. 
     
     
         21 . A method for assessing a lymphoma of a mammal, wherein said method comprises:
 (a) determining whether or not said lymphoma of said mammal has a translocation selected from the group consisting of IRF4 translocations, DUSP22 translocations, and FLJ43663 translocations, and   (b) classifying said mammal as having an anaplastic large-cell lymphoma if said lymphoma has said translocation.   
     
     
         22 . The method of  claim 21 , wherein said mammal is a human. 
     
     
         23 . A method for assessing a lymphoma of a mammal, wherein said method comprises:
 (a) determining whether or not said a cell of said lymphoma expresses an elevated level of an FLJ43663 mRNA or polypepide, and   (b) classifying said mammal as having an anaplastic large-cell lymphoma if said cell expresses said elevated level.   
     
     
         24 . The method of  claim 21 , wherein said mammal is a human.